To gain further insight into the biological functions of MT1X, we used the human VHL defective ccRCC line 786O to detect some of the genes typically targeted by cancer therapies that are a part of the hypoxia pathway. The gene discussed is MT1X; the disease is nonpapillary renal cell carcinoma.